USE-IT Trial: NEWS 2023

In the first, a consensus established relevant ultrasound parameters of activity, response, and healing. This first phase is completed!

The second phase is a reliability study in which inter- and intra-rater reliability of ultrasound parameters has been assessed. Four Centers were involved (Maaser – Lueneburg, Novak – Calgary, Nylund – Bergen, Wilkens – Copenhagen), 56 cine loops were reviewed separately from three blinded central readers, and statistical data analysis was done for the inter-rater variability. The fine tuning of the intra-rater variability is in progress, so we hope to have the final USE-IT Score by mid-May.

The third phase is going to validate the USE-IT score of activity and its responsiveness in 17 centers worldwide, and the recruitment started now. During this validation study, a total of 110 patients must be recruited. The results of the IUS examinations will be compared with the two gold standards, MRE and Colonoscopy.

To reward the efforts in patient inclusion, the top three recruiters will receive a special prize!

USE-IT Sites[60]

Finally, part IV aims to understand patient experience using depth focus groups with participants from the UK, Australia, USA, and Canada, in order to create the first patient-centered questionnaire on monitoring modalities. This questionnaire will be used in Part III as well. 

Two working groups are ongoing.

The first is on the role of Artificial Intelligence (AI) in imaging for the diagnosis and monitoring of inflammatory bowel disease, to detect gaps in the current applicability of Artificial Intelligence, and to drive areas for future research. The working group is currently preparing a systematic review on the topic use of AI in IBD.

The second is working on the gaps in the use of intestinal ultrasound in IBD in order to set the goals for future research in these fields. Let by Dr. Cathy Lu in Calgary, Canada.

We would like to conclude with the wish that more and more physicians taking care of IBD patients embrace the IBUS community and continue the IBUS journey with us. As always, we strongly welcome your interest and participation in SciCom.

Follow Us

Privacy Policy | Imprint
© Copyright IBUS 2021

Contact us +49 1706839752